-
Mashup Score: 0
Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Tune in to hear @DrMonzrAlMalki of @cityofhope and @JeffAuletta of @NMDP_org discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies. Watch here: https://t.co/ckO6DIZdmX
-
-
Mashup Score: 0
Marina Konopleva, MD, presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN, demonstrating its potent anti-tumor activity, rapid clearance of peripheral blasts, and restoration of normal hematopoiesis without cumulative myelosuppression.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Tune in to hear Marina Konopleva, MD, of @MontefioreNYC presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN. Watch more here: https://t.co/4axccKAXB9 https://t.co/N06ewp2vEh
-
-
Mashup Score: 0Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML - 5 day(s) ago
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Maximilian Stahl, MD, of @DanaFarber discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations. Read more here: https://t.co/KFA6pp3kFX
-
-
Mashup Score: 0
Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer #bcsm #oncology #MedEd https://t.co/2QucsGXOJl
-
-
Mashup Score: 2Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management - 5 day(s) ago
Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management @ASCO #GU25 #pcsm #oncology https://t.co/0SBzJDasYy
-
-
Mashup Score: 1
The FDA granted fast track designation to IBI363 for squamous non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC @US_FDA #lcsm #oncology https://t.co/y7oFNEaRFn
-
-
Mashup Score: 1OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer - 5 day(s) ago
Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer @DrSpratticus @caseccc @UHhospitals @ASCO #GU25 #oncology #pcsm https://t.co/DkLHCl3Q9p
-
-
Mashup Score: 2Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer - 5 day(s) ago
Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer @DrRanaMcKay @UCSanDiego @ASCO #GU25 #oncology https://t.co/DwRGW978t6
-
-
Mashup Score: 0
The FDA and European Commission have approved 2 biosimilars referencing denosumab for cancer-related bone loss and other indications.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Denosumab Biosimilars Win FDA, EU Approvals for Select Cancer-Related Bone Loss #oncology https://t.co/EqMFAY2vCj
-
Hear @NitinJainMD, of @MDAndersonNews and @drjoannarhodes1 of @RutgersCancer discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in CLL. https://t.co/5gNwDXHkC6 https://t.co/RZaf3cbabd